Combining AI-powered mRNA design with non-viral delivery to achieve organ-specific targeting

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Combining AI-powered mRNA design with non-viral delivery to achieve organ-specific targeting

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Attend this webinar to explore how cationic lipid-based transfection coupled with AI-powered mRNA design can enhance expression and tissue specificity for in vivo RNA delivery. Effective tissue-specific delivery remains a key challenge in the development of mRNA therapeutics. Achieving organ and tissue-specific delivery remains a perennial challenge for the mRNA-LNP therapeutic space, as ionizable LNPs predominantly accumulate in the liver, restricting their use for therapeutic development in other organs. In contrast, a transfection reagent based around LipidBrick®IM21.7c cationic lipid, offers an effective, simple and cost-efficient alternative with a broader biodistribution profile, enabling multi-organ mRNA delivery beyond the liver. Officinae Bio joins us to present case study data covering strategies for improved biodistribution using our transfection reagent, along with key considerations in the mRNA design space such as capping analogs and chemical modifications.

Attend this webinar to learn about:

Key benefits and drawbacks of LNPs versus cationic lipid-based transfection reagents for in vivo mRNA delivery
Exploring mRNA design spaces across UTRs, capping analogs, and chemical modifications that can improve targeted mRNA expression
Improving biodistribution beyond the liver while also simplifying processes and reducing costs

Claire Guéguen

R&D Life Sciences Manager at Sartorius Polyplus

Claire Guéguen serves as R&D Life Science Manager at Sartorius Polyplus. She earned her PhD in Immunology from the University of Paris-Saclay, in collaboration with Stallergenes Greer. Prio to joining Sartorius Polyplus, Claire spent five years at Adaptimmune in the R&D Department on TCR T-cell therapies and the generation of allogeneic T cells from iPSCs. At Sartorius Polyplus, she now leads the screening and development of innovative transfection reagents for in vitro and in vivo nucleic acid delivery.

Davide De Lucrezia

Vice President & General Manager at Officinae Bio

Davide is a synthetic biologist by training with a passion for bridging biology and computer science. He is co-founder and General Manager of Officinae Bio, now part of Maravai Life Sciences. Over the years, he has led multiple biotech ventures, focusing on innovation at the intersection between artificial intelligence and synthetic biology. His mission is to empower biologists to reprogram biology through smarter tools and streamlined workflows.